Taken together, our in vitro and in vivo results suggest that another potential mechanism by which STAT3 inhibition attenuates amyloid pathogenesis and its associated neurovascular deficits is by reducing Aβ-induced oxidative stress production and its pathologic impact on LRP-1 expression. This evidence concerns the gene STAT3 and amyloidosis.